Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06951971 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis

StatusNot Yet Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.
Trial Details
NCT Number NCT06951971
Lead Sponsor The First Affiliated Hospital of Soochow University
Conditions
(from sponsor)		 Hemophagocytic Lymphohistiocytosis (HLH)
Related terms Lymphohistiocytosis, Hemophagocytic
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov